title: Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
authors.forename: Linda A
authors.initials: LA
authors.lastname: Gallo
authors.forename: Micheal S
authors.initials: MS
authors.lastname: Ward
authors.forename: Amelia K
authors.initials: AK
authors.lastname: Fotheringham
authors.forename: Aowen
authors.initials: A
authors.lastname: Zhuang
authors.forename: Danielle J
authors.initials: DJ
authors.lastname: Borg
authors.forename: Nicole B
authors.initials: NB
authors.lastname: Flemming
authors.forename: Ben M
authors.initials: BM
authors.lastname: Harvie
authors.forename: Toni L
authors.initials: TL
authors.lastname: Kinneally
authors.forename: Shang-Ming
authors.initials: SM
authors.lastname: Yeh
authors.forename: Domenica A
authors.initials: DA
authors.lastname: McCarthy
authors.forename: Hermann
authors.initials: H
authors.lastname: Koepsell
authors.forename: Volker
authors.initials: V
authors.lastname: Vallon
authors.forename: Carol
authors.initials: C
authors.lastname: Pollock
authors.forename: Usha
authors.initials: U
authors.lastname: Panchapakesan
authors.forename: Josephine M
authors.initials: JM
authors.lastname: Forbes